The TULIP trial assessed efficacy of SYD985 in HER2-positive locally advanced or MBC that has been treated with two or more regimens.

Meeting Coverage > ASCO Pricey Drug Combo Boosts PFS in First-Line Advanced Ovarian Cancer — Questions about anti-PD-L1 contribution, cost, and access to durvalumab, bevacizumab, olaparib ...

Topline results from the company’s Veritac-2 trial (NCT05654623) showed a clinically meaningful improvement in PFS in ...

Oasmia barrels toward FDA filing after ovarian cancer drug clears PhIII By Nick Paul Taylor Apr 28, 2016 4:04am ovarian cancer Oasmia Clinical Data ...

CHICAGO—An investigational drug called axitinib is more effective than sorafenib in prolonging progression-free survival (PFS) in patients previously treated for metastatic renal cell carcinoma ...

Phase III trial data have demonstrated that therapy using Celgene’s Abraxane (paclitaxel protein-bound particles for injectable suspension; albumin-bound) leads to longer progression-free ...

The PFS benefit in the lung trial was driven by patients with non-squamous NSCLC, who had a median PFS of 5.6 months with Dato-DXd compared with 3.7 months with docetaxel (HR 0.63, 95% CI 0.51-0.78).

4SC AG has published convincing results from its clinical Phase II SHELTER study with the cancer drug resminostat as a second-line therapy for patients with advanced liver cancer (hepatocellular ...

Pre-Filled Syringes West Coast: SMi Groups latest instalment in the industry renowned Pre-Filled Syringes global event series welcoming industry leaders this June in San Diego, USA The conference ...

As many GEN poll voters agree as disagree that the primary endpoint for approval of cancer drugs should change to progression-free survival (PFS) from overall survival (OS), with 15.8% undecided ...

CHICAGO—An investigational drug called axitinib is more effective than sorafenib in prolonging progression-free survival (PFS) in patients previously treated for metastatic renal cell carcinoma ...